skip to main content
Close Icon We use cookies to improve your website experience.  To learn about our use of cookies and how you can manage your cookie settings, please see our Cookie Policy.  By continuing to use the website, you consent to our use of cookies.
Global Search Configuration

Cyprium joins Fortress’ growing company portfolio, which now includes nine subsidiaries focused on a broad range of disease. Fortress CEO Rosenwald aims to add one to two new companies a quarter under the Fortress umbrella.






Fortress Biotech Inc. unveiled a new subsidiary March 14, Cyprium Therapeutics, Inc. focused on treatments for the rare pediatric genetic disease Menkes disease and related copper metabolism disorders. Fortress now has nine companies under its umbrella, several of which are developing drugs for rare diseases.


Fortress, which finances each subsidiary company separately and through various means, while retaining an economic stake, has a goal of bringing in one or two new portfolio companies quarterly. The firm’s 20-person business development team is hard at work scouring the life sciences sector for assets, CEO Lindsay Rosenwald said in an interview at the company’s New York City headquarters March 8.


Days later, Fortress followed through on its company-building ambitions by announcing the formation of Cyprium.


The new company will be focused on the development of the Phase III candidate CUTX-101 for the treatment of Menkes disease, a rare pediatric disease caused by genetic mutation of copper transporter ATP7A that affects one in 100,000 newborns each year. Menkes patients often have low levels of copper in their blood and brain, and clinical features of the disease include connective tissue disorders and severe neurological symptoms such as seizures. Many patients die before the age of three.


Milder versions of ATP7A mutations are associated with other diseases, including Occipital Horn Syndrome and ATP7A-related Distal Motor Neuropathy. There are no FDA-approved treatments for Menkes disease and its variants, according to Fortress.


CUTX-101 is a subcutaneous injectable formulation of copper histidinate. Cyprium will develop the drug under a Cooperative Research and Development Agreement (CRADA) with the Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), part of the National Institutes of Health. Cyprium and NICHD have also entered into an exclusive license agreement to develop and commercialize an adeno-associated virus (AAV)-based gene therapy, AAV-ATP7A, to deliver copies of the copper transporter that is defective in Menkes patient and be used in combination with CUTX-101.


In Phase I/II clinical studies conducted by NICHD, early treatment of Menkes patients with CUTX-101 led to an improvement in neurodevelopmental outcomes and survival. The gene therapy is in preclinical development at NICHD.


The next step for Cyprium will be to work with NICHD to conduct a retrospective natural history study to collect data on Menkes disease patients who have not been treated with copper supplements. The data could be used as a historical control in a future study. The company expects to request a meeting with FDA in 2017 to determine the regulatory path forward for CUX-101.


Fortress simultaneously announced the appointment of Lung Yam as CEO of Cyprium, one of the company’s business development consultants who identified the opportunity to in-license CUTX-101 and the AAV-ATP7A gene therapy program. Yam also serves as a senior analyst at the life science asset management firm Opus Point Partners.



Adding To the Rare Disease Portfolio


Cyprium joins eight other subsidiaries at Fortress, which Rosenwald has shaped into an asset-funding parent company since taking over as CEO in December 2013. The longtime biotech entrepreneur previously worked as a portfolio manager at Opus Point Partners, and he saw an opportunity to fund multiple start-ups at once in a flexible way.


“You can’t raise enough money every year inside of one small company” to fund all the programs Fortress is shepherding, Rosenwald said. “The only reason we do the subsidiaries is because that’s how you finance these things.” Another advantage of the subsidiary structure is the various focused management teams working to move the assets under their respective companies forward.


Fortress is agnostic about what therapy area it invests in, but has focused in pediatric rare diseases, liver diseases, acute care and oncology.


“We do pick areas where we feel there is a huge unmet medical need where we think we could have an impact,” Rosenwald said.


Fortress’ companies operate out of a swanky open office in Manhattan’s Meatpacking district, with a pool table and roof deck, and plenty of room for more employees to join the team. Rosenwald hopes the company will eventually run more of its own R&D and manufacturing operations too. For now, the focus is on progressing drugs in the pipeline, adding new companies to the portfolio and monetizing some assets through partnerships.


Read also


Next steps

Whether you’re a small biotech start-up, research firm, generic manufacturer or a global pharmaceutical giant, you need focused, independent insight and opinion on market developments.

Our team is ready to hear from you for a particular request or area of interest. Please do not hesitate to reach out and discuss.

Contact us for product technical and account support.

  • US Toll-Free   : +1 888 670 8900 
  • US Toll             : +1 212-600-3520
  • UK & Europe : +44 (0) 208 052 0700

Have an immediate and specific information need?

Browse and buy from 1000s of analysis and research reports now: